Annual report pursuant to Section 13 and 15(d)

Research and Development Agreements - Additional Information (Detail)

v3.23.1
Research and Development Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2021
Feb. 28, 2021
Sep. 30, 2018
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Research And Development Collaboration Agreements [Line Items]              
Research and development revenue recognized       $ 2,600,000   $ 19,754,000 $ 38,697,000
Revenue from grant           19,754,000 38,697,000
Grant              
Research And Development Collaboration Agreements [Line Items]              
Revenue from grant           0 0
CPRIT Agreement | Cancer Prevention and Research Institute of Texas              
Research And Development Collaboration Agreements [Line Items]              
Product development grant awarded     $ 15,200,000        
Grant Agreements | Grants Revenue Receivable              
Research And Development Collaboration Agreements [Line Items]              
Reimbursement amounts submitted in excess of amounts received are recorded as receivables         $ 0 0 0
Bristol Myers Squibb Collaboration Agreement              
Research And Development Collaboration Agreements [Line Items]              
Upfront payment   $ 70,000,000.0          
Milestone payments receivable if option is exercised   874,500,000          
Transaction price allocated to performance obligations   70,000,000.0          
Deferred revenue, current         32,800,000 45,300,000 32,800,000
Deferred revenue, non-current         30,700,000 5,900,000 30,700,000
Bristol Myers Squibb Collaboration Agreement | Sales Milestone              
Research And Development Collaboration Agreements [Line Items]              
Milestone payments receivable if option is exercised   $ 450,000,000.0          
Vertex Collaboration Agreement              
Research And Development Collaboration Agreements [Line Items]              
Research and development revenue recognized         14,600,000    
Deferred revenue         0 0 0
Takeda Development Agreement              
Research And Development Collaboration Agreements [Line Items]              
Deferred revenue         0 0 0
Takeda Development Agreement | Maximum              
Research And Development Collaboration Agreements [Line Items]              
Clinical and regulatory milestone payments $ 22,250,000            
Takeda Multi Target Agreement | Takeda Pharmaceuticals Inc              
Research And Development Collaboration Agreements [Line Items]              
Deferred revenue         $ 2,600,000 $ 0 $ 2,600,000